Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 1/20 | 0.51 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.51 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14731447 | 0.89 | MEN1 (0.53) | TPSAB1ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL861454 | 0.88 | ERCC1 (0.49) | ERCC1ERCC4TPSAB1ALDH1A1L3MBTL1 | |
| SCHEMBL860798 | 0.83 | TPSAB1 (0.54) | TPSAB1ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL12131750 | 0.82 | ERCC1 (0.70) | ERCC1ERCC4TPSAB1MEN1KMT2A | |
| SCHEMBL16205822 | 0.81 | TPSAB1 (0.57) | TPSAB1ALDH1A1L3MBTL1HTTMEN1 | |
| SCHEMBL16273562 | 0.80 | HTT (0.59) | TPSAB1ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL15682817 | 0.80 | ALDH1A1 (0.69) | TPSAB1ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL861031 | 0.78 | MAPT (0.56) | TPSAB1ALDH1A1L3MBTL1HTTMEN1 | |
| SCHEMBL861426 | 0.78 | MEN1 (0.56) | TPSAB1ALDH1A1L3MBTL1HTTMEN1 | |
| SCHEMBL12757447 | 0.78 | ALDH1A1 (0.62) | ERCC1ERCC4ALDH1A1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143302-B2 | Methods and compositions for diagnostic and therapeutic targeting of COX-2 | VANDERBILT UNIVERSITY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | PTGS2, PTGES2, PTGER2 | ERCC1 3289/4885ERCC4 2832/4885TPSAB1 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.